Effect of simvastatin on the pharmacokinetics of sitagliptin

Journal of Population Therapeutics and Clinical Pharmacology

Volumn 19, Issue 3, 2012, Pages

  Cerra, Michael ^a   Luo, Wen Lin ^a  

^a Xiujiang)   (United States)

Author keywords

Atherosclerosis; Diabetes; Dipeptidyl peptidase 4; Drug interactions; HMG CoA reductase; Statin; Type

Indexed keywords

SIMVASTATIN; SITAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; CONTROLLED CLINICAL TRIAL; DRUG INTERACTION; MIDDLE AGED;

ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRAZINES; SIMVASTATIN; TRIAZOLES; YOUNG ADULT;

EID: 84867662710     PISSN: 17106222     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
2. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974;23:105-11.
3. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Brit Med J 2000;321:405-12.
4. American Diabetes Association. Standards of Medical Care in Diabetes-2011. Diabetes Care 2011;34:S11-S61.
5. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136.
6. Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin 2008;24:489-96.
7. Thornberry NA, Weber AE. Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr Top Med Chem 2007;7:557-68.
8. Pedersen TR, Tobert JA. Simvastatin: a review. Expert Opin Pharmacother 2004;5:2583-96.
9. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomized trials of statins: a meta-analysis. Lancet 2008;371:117-25.
10. U.S. Food and Drug Administration. FDA approves combination therapy Juvisync [press release]. U.S. Food and Drug Administration. (October 7, 2011) http://www.fda.gov/NewsEvents/Newsroom/Pre ssAnnouncements/ucm274748.htm (Accessed April 3, 2012).
11. Bergman AJ, Cote J, Maes A, et al. Effect of sitagliptin on the pharmacokinetics of simvastatin. J Clin Pharmacol 2009;49:483-8.
12. Ayalasomayajula SP, Dole K, He YL, et al. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Curr Med Res Opin 2007;23:2913-20.
13. Zeng W, Xu Y, Constanzer M, Woolf EJ. Determination of sitagliptin in human plasma using protein precipitation and tandem mass spectrometry. J Chromatography B 2010;878:1817-23.
14. Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-88.
15. Vincent SH, Reed JR, Bergman AJ, et al. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 2007;35:533-8.
16. Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol 2003;56:120-4.
17. U.S. prescribing information for JANUVIA® (sitagliptin) Tablets. (September 2010) http://www.januvia.com/sitagliptin/januvia/cons umer/index.jsp (Accessed April 3, 2012).
18. Bergman A, Mistry GC, Luo WL, et al. Doseproportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos 2007;28:307-13.